Travere Therapeutics (TVTX) Competitors $14.50 -0.44 (-2.95%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.50 +0.01 (+0.03%) As of 06/13/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. ADMA, PCVX, AKRO, RYTM, ZLAB, PTCT, CYTK, RNA, KRYS, and SRPTShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include ADMA Biologics (ADMA), Vaxcyte (PCVX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Avidity Biosciences (RNA), Krystal Biotech (KRYS), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Its Competitors ADMA Biologics Vaxcyte Akero Therapeutics Rhythm Pharmaceuticals Zai Lab PTC Therapeutics Cytokinetics Avidity Biosciences Krystal Biotech Sarepta Therapeutics ADMA Biologics (NASDAQ:ADMA) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment. Does the MarketBeat Community prefer ADMA or TVTX? ADMA Biologics received 319 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 72.05% of users gave ADMA Biologics an outperform vote while only 61.94% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformADMA BiologicsOutperform Votes41572.05% Underperform Votes16127.95% Travere TherapeuticsOutperform Votes9661.94% Underperform Votes5938.06% Which has higher earnings and valuation, ADMA or TVTX? ADMA Biologics has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$459.38M10.81-$28.24M$0.8524.48Travere Therapeutics$273.53M4.71-$111.40M-$2.81-5.16 Is ADMA or TVTX more profitable? ADMA Biologics has a net margin of 17.80% compared to Travere Therapeutics' net margin of -137.90%. ADMA Biologics' return on equity of 53.20% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics17.80% 53.20% 26.07% Travere Therapeutics -137.90%-1,636.87%-55.95% Do insiders and institutionals have more ownership in ADMA or TVTX? 75.7% of ADMA Biologics shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by company insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ADMA or TVTX? ADMA Biologics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Do analysts recommend ADMA or TVTX? ADMA Biologics currently has a consensus price target of $24.25, indicating a potential upside of 16.53%. Travere Therapeutics has a consensus price target of $32.14, indicating a potential upside of 121.67%. Given Travere Therapeutics' higher possible upside, analysts plainly believe Travere Therapeutics is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 Does the media favor ADMA or TVTX? In the previous week, Travere Therapeutics had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 21 mentions for Travere Therapeutics and 14 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.01 beat Travere Therapeutics' score of 0.48 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryADMA Biologics beats Travere Therapeutics on 14 of the 19 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E Ratio-3.548.4326.6319.64Price / Sales4.71262.52407.99152.12Price / CashN/A65.8538.2534.64Price / Book5.436.536.964.60Net Income-$111.40M$143.25M$3.23B$248.06M7 Day Performance-5.35%-0.06%-1.13%-0.94%1 Month Performance-31.25%11.77%8.59%3.52%1 Year Performance102.23%3.66%33.63%14.02% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.478 of 5 stars$14.50-2.9%$32.14+121.7%+100.3%$1.29B$273.53M-3.54460Trending NewsAnalyst ForecastAnalyst RevisionADMAADMA Biologics2.3499 of 5 stars$20.87+1.3%$24.25+16.2%+93.0%$4.98B$459.38M74.54530Positive NewsInsider TradeAnalyst RevisionPCVXVaxcyte3.1594 of 5 stars$37.20+0.6%$136.50+266.9%-53.3%$4.80BN/A-8.09160Positive NewsAnalyst RevisionGap DownAKROAkero Therapeutics3.6132 of 5 stars$54.71+0.8%$82.50+50.8%+125.9%$4.36BN/A-14.5930Trending NewsInsider TradeGap DownHigh Trading VolumeRYTMRhythm Pharmaceuticals4.1447 of 5 stars$66.72-2.0%$76.62+14.8%+41.8%$4.24B$136.86M-15.41140Insider TradeZLABZai Lab1.2796 of 5 stars$37.87-0.6%$47.37+25.1%+108.2%$4.18B$418.33M-13.671,950Positive NewsAnalyst RevisionPTCTPTC Therapeutics3.8498 of 5 stars$51.69-0.8%$63.75+23.3%+38.9%$4.10B$1.77B-8.701,410Analyst RevisionGap DownCYTKCytokinetics4.2636 of 5 stars$33.13+2.6%$70.92+114.1%-34.8%$3.96B$19.22M-6.16250Analyst RevisionRNAAvidity Biosciences2.0841 of 5 stars$32.66-9.9%$67.62+107.0%-21.5%$3.94B$8.93M-11.34190Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading VolumeKRYSKrystal Biotech4.5409 of 5 stars$136.08-0.6%$211.13+55.1%-25.0%$3.93B$333.45M45.51210Positive NewsAnalyst RevisionSRPTSarepta Therapeutics4.7137 of 5 stars$39.71-7.7%$122.61+208.8%-71.1%$3.90B$2.23B31.77840Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ADMA Biologics Competitors Vaxcyte Competitors Akero Therapeutics Competitors Rhythm Pharmaceuticals Competitors Zai Lab Competitors PTC Therapeutics Competitors Cytokinetics Competitors Avidity Biosciences Competitors Krystal Biotech Competitors Sarepta Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
